WO2001032695A3 - MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF - Google Patents

MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF Download PDF

Info

Publication number
WO2001032695A3
WO2001032695A3 PCT/US2000/030294 US0030294W WO0132695A3 WO 2001032695 A3 WO2001032695 A3 WO 2001032695A3 US 0030294 W US0030294 W US 0030294W WO 0132695 A3 WO0132695 A3 WO 0132695A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
vegf
therapeutic uses
enos activity
receptor agonists
Prior art date
Application number
PCT/US2000/030294
Other languages
French (fr)
Other versions
WO2001032695A2 (en
Inventor
Ben-Quan Shen
Thomas Zioncheck
Original Assignee
Genentech Inc
Shen Ben Quan
Thomas Zioncheck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Shen Ben Quan, Thomas Zioncheck filed Critical Genentech Inc
Priority to EP00980281A priority Critical patent/EP1225910A2/en
Priority to CA002385665A priority patent/CA2385665A1/en
Priority to AU17565/01A priority patent/AU782158B2/en
Priority to IL14867400A priority patent/IL148674A0/en
Priority to US09/700,806 priority patent/US7078382B1/en
Priority to JP2001535394A priority patent/JP2003513105A/en
Publication of WO2001032695A2 publication Critical patent/WO2001032695A2/en
Publication of WO2001032695A3 publication Critical patent/WO2001032695A3/en
Priority to US11/346,596 priority patent/US20060188503A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides uses of VEGF or VEGF receptor agonists for the up-regulation of eNOS expression and activity. VEGF and VEGF receptor agonists are useful in the treatment of or prevention from hypertension, diabetes, angina, thrombosis, atherosclerosis, heart failure, and other conditions or disorders wherein nitric oxide is an important regulator.
PCT/US2000/030294 1999-11-02 2000-11-02 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF WO2001032695A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00980281A EP1225910A2 (en) 1999-11-02 2000-11-02 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
CA002385665A CA2385665A1 (en) 1999-11-02 2000-11-02 Modulation of enos activity and therapeutic uses thereof
AU17565/01A AU782158B2 (en) 1999-11-02 2000-11-02 Modulation of eNOS activity and therapeutic uses thereof
IL14867400A IL148674A0 (en) 1999-11-02 2000-11-02 Modulation of enos activity and therapeutic uses thereof
US09/700,806 US7078382B1 (en) 1999-11-02 2000-11-02 Modulation of eNOS activity and therapeutic uses thereof
JP2001535394A JP2003513105A (en) 1999-11-02 2000-11-02 Modulation of eNOS activity and its therapeutic use
US11/346,596 US20060188503A1 (en) 1999-11-02 2006-02-02 Modulation of eNOS activity and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16313299P 1999-11-02 1999-11-02
US60/163,132 1999-11-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/346,596 Continuation US20060188503A1 (en) 1999-11-02 2006-02-02 Modulation of eNOS activity and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
WO2001032695A2 WO2001032695A2 (en) 2001-05-10
WO2001032695A3 true WO2001032695A3 (en) 2002-02-14

Family

ID=22588624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030294 WO2001032695A2 (en) 1999-11-02 2000-11-02 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF

Country Status (6)

Country Link
EP (1) EP1225910A2 (en)
JP (1) JP2003513105A (en)
AU (1) AU782158B2 (en)
CA (1) CA2385665A1 (en)
IL (1) IL148674A0 (en)
WO (1) WO2001032695A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799258A4 (en) * 2004-08-20 2009-07-22 Univ Johns Hopkins Methods for treatment of angiogenesis
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008313A1 (en) * 1995-08-25 1997-03-06 Genentech, Inc. Variants of vascular endothelial cell growth factor, their uses, and processes for their production
WO1998016551A2 (en) * 1996-10-17 1998-04-23 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties
WO1998020027A2 (en) * 1996-11-01 1998-05-14 Eurogene Limited Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
US5955311A (en) * 1994-02-10 1999-09-21 Imclone Systems Incorporated Monoclonal antibodies specific to VEGF receptors and uses thereof
WO2000013702A2 (en) * 1998-09-09 2000-03-16 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
WO2000063380A1 (en) * 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
WO2000071713A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955311A (en) * 1994-02-10 1999-09-21 Imclone Systems Incorporated Monoclonal antibodies specific to VEGF receptors and uses thereof
WO1997008313A1 (en) * 1995-08-25 1997-03-06 Genentech, Inc. Variants of vascular endothelial cell growth factor, their uses, and processes for their production
WO1998016551A2 (en) * 1996-10-17 1998-04-23 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties
WO1998020027A2 (en) * 1996-11-01 1998-05-14 Eurogene Limited Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
WO2000013702A2 (en) * 1998-09-09 2000-03-16 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
WO2000063380A1 (en) * 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
WO2000071713A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARADA K ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR ADMINISTRATION IN CHRONIC MYOCARDIAL ISCHEMIA", AMERICAN JOURNAL OF PHYSIOLOGY: HEART AND CIRCULATORY PHYSIOLOGY, THE AMERICAN PHYSIOLOGICAL SOCIETY, XX, vol. 270, no. 5, PART 2, May 1996 (1996-05-01), pages H1791 - H1802, XP000946368, ISSN: 0363-6135 *
LAITINEN M ET AL: "VEGF GENE TRANSFER REDUCES INTIMAL THICKENING VIA INCREASED PRODUCTION OF NITRIC OXIDE IN CAROTID ARTERIES", HUMAN GENE THERAPY, XX, XX, vol. 8, no. 15, 10 October 1997 (1997-10-10), pages 1737 - 1744, XP002072657, ISSN: 1043-0342 *
MORBIDELLI L ET AL: "NITRIC OXIDE MEDIATES MITOGENIC EFFECT OF VEGF ON CORONARY VENULAR ENDOTHELIUM", AMERICAN JOURNAL OF PHYSIOLOGY: HEART AND CIRCULATORY PHYSIOLOGY, THE AMERICAN PHYSIOLOGICAL SOCIETY, XX, vol. 270, no. 1, PART 2, 1996, pages H411 - H415, XP002072656, ISSN: 0363-6135 *
ZACHARY I ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULATES NITRIC OXIDE PRODUCTION AND PROSTACYCLIN SYNTHESIS IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS", EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 18, no. SUPPL, 24 August 1997 (1997-08-24), pages 4, XP002072658, ISSN: 0195-668X *

Also Published As

Publication number Publication date
EP1225910A2 (en) 2002-07-31
AU1756501A (en) 2001-05-14
WO2001032695A2 (en) 2001-05-10
JP2003513105A (en) 2003-04-08
AU782158B2 (en) 2005-07-07
CA2385665A1 (en) 2001-05-10
IL148674A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2001042265A3 (en) N6 heterocyclic 8-modified adenosine derivatives
WO2001040243A3 (en) Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives
WO2004052284A3 (en) Treatment of diabetes
WO1999007736A3 (en) Lipoprotein-regulating medicaments
DE69821132D1 (en) 1,3-THIAZOLE AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING ASTHMA, ALLERGIES AND DIABETES
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
EP2319527A3 (en) BAFF, inhibitors thereof and their use in the modulation of the B-cell response
WO2002099054A3 (en) Hccss as modifiers of the p53 pathway and methods of use
WO1998046257A8 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
WO1999057144A3 (en) Human transcriptional regulator molecules
EP1423133A4 (en) Treatment of muscular dystrophies and related disorders
BR0311161A (en) Diabetes Treatment Method
WO2001032695A3 (en) MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
WO2002098891A3 (en) GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002074193A3 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
WO2001005353A3 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
NZ331789A (en) Method of treating heart failure with non-peptide endothelin antagonists
WO2005021026A3 (en) Methods for treating or ameliorating ghrelin-associated diseases and disorders
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2000063351A3 (en) Carbohydrate-modifying enzymes
EP1438432A4 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
IDP000009286A (en) COMPOSITION AND METHODS FOR TREATMENT OF ATOPIC DERMATITIS, ANGIOEDEMA AND OTHER DISORDERS USING ANTIHISTAMIN AND GLUCOCORTICOID
WO2000078952A8 (en) Human rna metabolism proteins (rmep)
UA31635A (en) Method for assessing efficacy of hemodynamic normalization in treating hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09700806

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 148674

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2385665

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000980281

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 535394

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 17565/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000980281

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 17565/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000980281

Country of ref document: EP